$1.62 -0.01 (-0.61%)
12/3/2009 3:59 PM

Labopharm, Inc. (DDSS)

CAPS Rating: 3 out of 5

An international, specialty pharmaceutical company focused on improving existing drugs by incorporating its proprietary, advanced controlled-release technologies.

Recs

0
Member Avatar Gumfactor (86.88) Submitted: 6/29/2007 2:40:18 PM : Outperform Start Price: $2.85 DDSS Score: +11.18

A nice Canadian biotech company with moderate near-term profit potential. The stock has been beaten way down in the past month because of a 2nd 'approvable' letter from the FDA regarding tramadol. But tramadol just gained approval in Canada, and I anticipate that they'll eventually get this through the FDA as well. When it does, you can expect an instant 300% profit. Meanwhile, the stock sits at a point too damn low for a company with DDSS's potential. Even while the market waits to see what the result of talks with the FDA are, I expect a healthy correction back into the $4.00 range. While the company remains partially under the radar, it was just raised from 'sell' to 'hold' by one of the few analysts.

Report this Post 0 Comments

Featured Broker Partners